Search - tctmd.com

Displaying 41 - 60 of 83

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

News Daily News

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

December 22, 2021

Discharge Safe as Early as a Day After Primary PCI for STEMI

News Daily News

Discharge Safe as Early as a Day After Primary PCI for STEMI

December 15, 2021

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

News Daily News

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

December 03, 2021

December 2021 News Roundup

News Opinion CV Team Dispatch

December 2021 News Roundup

December 01, 2021

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

News Daily News

No Uptick in CVD Events After COVID-19 Vaccination in Older Adults

Michael O'Riordan

November 29, 2021

News Daily News

Shock in COVID-19: Types, Triggers, and Treatments Differ, but Outlook Is Grim

November 24, 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

News Conference News TCT 2021

Mortality High in Patients With STEMI, COVID-19 on Hemodynamic Support

November 11, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

News Daily News

USPSTF at Last Takes Tougher Stance on Aspirin in Primary Prevention

October 15, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

TCTMD’s Top 10 Most Popular Stories for August 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for August 2021

September 03, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 4

August 22, 2021

COVID-19 Infection Boosts Acute MI, Stroke Risk in Early Weeks

News Daily News

COVID-19 Infection Boosts Acute MI, Stroke Risk in Early Weeks

August 03, 2021

July/August 2021 News Roundup

News Opinion CV Team Dispatch

July/August 2021 News Roundup

August 01, 2021

COVID-19: TCTMD’s Daily Dispatch for August Week 1

News Daily News

COVID-19: TCTMD’s Daily Dispatch for August Week 1

August 01, 2021

COVID-19: TCTMD’s Daily Dispatch for July Week 4

News Daily News

COVID-19: TCTMD’s Daily Dispatch for July Week 4

July 26, 2021

COVID-19: TCTMD’s Daily Dispatch for July Week 3

News Daily News

COVID-19: TCTMD’s Daily Dispatch for July Week 3

July 19, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.